4D Molecular Therapeutics, Inc. 10-Q filing
Filed 2026-05-07 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001193125-26-211939
- Form type
- 10-Q
- CIK
- 0001650648
- Primary document
- https://www.sec.gov/Archives/edgar/data/1650648/000119312526211939/fdmt-20260331.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for 4D Molecular Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $3.0M | - | - |
| Operating Income | $-73.6M | - | - |
| Net Income | $-68.8M | - | - |
| Eps Basic | -1.01 | - | - |
| Eps Diluted | -1.01 | - | - |
| Cash And Equivalents | $72.5M | - | - |
| Total Assets | $512.9M | - | - |
| Total Liabilities | $61.1M | - | - |
| Shareholders Equity | $451.8M | - | - |
| Operating Cash Flow | $-68.1M | - | - |